A Phase1B Study: A Placebo Controlled Study of PF-03654746 Given as Add-On Treatment of Cognitive Deficits in Schizophrenia
Latest Information Update: 05 May 2011
At a glance
- Drugs PF 3654746 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 05 May 2011 New trial record